New hope for progressive MS: drug trial targets disability

NCT ID NCT07067463

Recruiting now Disease control Sponsor: Zenas BioPharma (USA), LLC Source: ClinicalTrials.gov ↗

First seen Dec 11, 2025 · Last updated May 14, 2026 · Updated 19 times

Summary

This study tests an experimental drug called orelabrutinib against a placebo in people with primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens over time. The goal is to see if the drug can delay or prevent disability progression, such as walking or hand function decline. About 705 adults aged 18 to 60 with PPMS will take the drug or placebo for at least 12 months, and researchers will track changes in disability scores.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurology Associates, PA
RECRUITING

Maitland, Florida, 32751, United States
Premier Neurology
RECRUITING

Greenville, South Carolina, 29605, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS (MS) PRIMARY PROGRESSIVE